Literature DB >> 28400203

Transcriptomic and genomic features of invasive lobular breast cancer.

Christine Desmedt1, Gabriele Zoppoli2, Christos Sotiriou3, Roberto Salgado4.   

Abstract

Accounting for 10-15% of all breast neoplasms, invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal breast cancer (IDC). Understanding ILC biology, which differs from IDC in terms of clinical presentation, treatment response, relapse timing and patterns, is essential in order to adopt novel, disease-specific management strategies. While the contribution of the histological subtypes to tumour biology has been poorly investigated and acknowledged in the past, recently several major, independent efforts have led to the assembly and molecular characterization of well-annotated ILC case sets. In this review, we provide a critical overview of the literature exploring ILC, through comprehensive and multiomic methods. The first part specifically focuses on ILC transcriptomic features by reviewing the intrinsic molecular subtypes, the application of gene expression scores for the prediction of recurrence, and the identification of gene expression subtypes. The second part describes the main research efforts that lead to the identification of the genomic landscape of ILC, with a special focus to findings that differentiate ILC from IDC and carry potential clinical relevance.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gene expression; Immune; Intrinsic subtypes; Invasive lobular breast cancer; Prognostic classifiers; Proteomics; Sequencing; mutations

Mesh:

Year:  2017        PMID: 28400203     DOI: 10.1016/j.semcancer.2017.03.007

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  13 in total

1.  SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma.

Authors:  Emily A Bossart; Nilgun Tasdemir; Matthew J Sikora; Amir Bahreini; Kevin M Levine; Jian Chen; Ahmed Basudan; Britta M Jacobsen; Timothy F Burns; Steffi Oesterreich
Journal:  Breast Cancer Res Treat       Date:  2019-02-23       Impact factor: 4.872

2.  Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.

Authors:  Anthony Bergeron; Gaëtan MacGrogan; Aurélie Bertaut; Sylvain Ladoire; Patrick Arveux; Isabelle Desmoulins; Hervé Bonnefoi; Catherine Loustalot; Sophie Auriol; Françoise Beltjens; Emilie Degrolard-Courcet; Céline Charon-Barra; Corentin Richard; Romain Boidot; Laurent Arnould
Journal:  Mod Pathol       Date:  2021-03-22       Impact factor: 8.209

3.  Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.

Authors:  Max A K Rätze; Thijs Koorman; Thijmen Sijnesael; Blessing Bassey-Archibong; Robert van de Ven; Lotte Enserink; Daan Visser; Sridevi Jaksani; Ignacio Viciano; Elvira R M Bakker; François Richard; Andrew Tutt; Lynda O'Leary; Amanda Fitzpatrick; Pere Roca-Cusachs; Paul J van Diest; Christine Desmedt; Juliet M Daniel; Clare M Isacke; Patrick W B Derksen
Journal:  Oncogene       Date:  2022-04-18       Impact factor: 8.756

4.  Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience.

Authors:  Ga-Jing Kee; Ryan Ying-Cong Tan; Sultana Rehena; Joycelyn Jie-Xin Lee; Ma Wai-Wai Zaw; Wei-Xiang Lian; Joe Yeong; Su-Ming Tan; Swee-Ho Lim; Benita Kiat-Tee Tan; Yoon-Sim Yap; Rebecca Alexandra Dent; Fuh-Yong Wong; Guek-Eng Lee
Journal:  World J Clin Oncol       Date:  2020-05-24

5.  Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model.

Authors:  Luisa Carbognin; Michele Simbolo; Anna Caliò; Caterina Vicentini; Pietro Delfino; Isabella Sperduti; Matteo Fassan; Francesco Schettini; Maria Vittoria Dieci; Gaia Griguolo; Sara Pilotto; Elena Fiorio; Grazia Arpino; Valentina Guarneri; Sabino De Placido; Pierfranco Conte; Erminia Manfrin; Matteo Brunelli; Giovanni Scambia; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Breast       Date:  2020-01-27       Impact factor: 4.380

6.  Differential expression of PMCA2 mRNA isoforms in a cohort of Spanish patients with breast tumor types.

Authors:  Alicia Romero-Lorca; Maria Gaibar; Angel Luis Armesilla; Ana Fernandez-Santander; Apolonia Novillo
Journal:  Oncol Lett       Date:  2018-10-02       Impact factor: 2.967

7.  The Distribution of Circulating Tumor Cells Is Different in Metastatic Lobular Compared to Ductal Carcinoma of the Breast-Long-Term Prognostic Significance.

Authors:  Ulrik Narbe; Pär-Ola Bendahl; Kristina Aaltonen; Mårten Fernö; Carina Forsare; Charlotte Levin Tykjær Jørgensen; Anna-Maria Larsson; Lisa Rydén
Journal:  Cells       Date:  2020-07-17       Impact factor: 6.600

8.  Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.

Authors:  Zheling Chen; Jiao Yang; Shuting Li; Meng Lv; Yanwei Shen; Biyuan Wang; Pan Li; Min Yi; Xiao'ai Zhao; Lingxiao Zhang; Le Wang; Jin Yang
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

9.  Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast.

Authors:  Yeji An; Jessica R Adams; Daniel P Hollern; Anthony Zhao; Stephen G Chang; Miki S Gams; Philip E D Chung; Xiaping He; Rhea Jangra; Juhi S Shah; Joanna Yang; Lauren A Beck; Nandini Raghuram; Katelyn J Kozma; Amanda J Loch; Wei Wang; Cheng Fan; Susan J Done; Eldad Zacksenhaus; Cynthia J Guidos; Charles M Perou; Sean E Egan
Journal:  Cell Rep       Date:  2018-10-16       Impact factor: 9.423

10.  Transcriptomics and Prognosis Analysis to Identify Critical Biomarkers in Invasive Breast Carcinoma.

Authors:  Jun Wu; Xiao-Jun Liu; Jia-Nan Hu; Xu-Hui Liao; Fei-Fei Lin
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.